Loading...
•
Jun 30
Bridgebio Q2 2025 Earnings Report
BridgeBio posted strong revenue growth in Q2 2025 driven by the launch of Attruby and milestone licensing revenue.
Key Takeaways
BridgeBio reported $110.6M in total revenue for Q2 2025, driven by $71.5M in Attruby product sales and $37.5M in license and services revenue. However, the company posted a net loss of $181.9M due to higher SG&A expenses supporting the commercial launch.
Total revenue reached $110.6M, up from $2.2M in Q2 2024.
Attruby generated $71.5M in net product revenue during its first full commercial quarter.
BridgeBio reported a net loss of $181.9M, with EPS of -$0.95.
Cash and marketable securities increased to $756.9M, supported by royalty and note issuances.
Bridgebio
Bridgebio
Bridgebio Revenue by Segment
Revenue by Segment
License Revenue
CapyFin.comProduct Revenue
CapyFin.comRoyalty Revenue
CapyFin.com Forward Guidance
BridgeBio anticipates a transformative six months with multiple Phase 3 trial readouts and continued momentum for Attruby.
Positive Outlook
- Phase 3 readouts for BBP-418 and Encaleret expected in Fall 2025.
- Attruby is experiencing accelerating adoption across prescribers.
- Cash reserves of $756.9M provide runway for clinical execution.
- License milestone from Alexion contributed $30M in Q2 revenue.
- BEYONTTRA royalty monetization raised $300M in non-dilutive capital.
Challenges Ahead
- Net loss increased to $181.9M in Q2 due to higher SG&A expenses.
- Operating expenses rose 38% YoY primarily due to commercial investments.
- Royalty revenue remains relatively modest at $1.6M in Q2.
- Attruby faces competition and must maintain launch momentum.
- Non-operating losses increased due to equity method investments and interest expense.